ArticleFrontiers in endocrinology2026
Pentraxin-3 in thyroid nodules: a systemic marker of pathology and a local mediator of inflammation and carcinoma.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thyroid nodules are extremely common, yet the exact physio-pathological mechanisms underlying their benign or malignant development remain poorly understood. Pentraxin-3 (PTX3) is an innate immune inflammatory mediator involved in inflammation, tissue remodeling, and oncogenesis, processes often coexistent in thyroid pathology. This study evaluated plasma and tissue PTX3 in patients undergoing thyroidectomy for benign or malignant nodules. Methods: A total of 52 patients were enrolled. Plasma PTX3 levels were assessed by ELISA before surgery and again 45 days afterward. PTX3 expression, along with the abundance of two immune cell populations (e.g. macrophages and mast cells) was evaluated by immunohistochemistry using a tissue microarray. Results: Preoperative plasma PTX3 levels were significantly elevated (4.58 ng/mL, p<0.05) compared with the normal reference range and declined significantly after surgery (3.58 ng/mL, p<0.05). No significant differences in plasma PTX3 were observed between benign and malignant conditions. In tissue analysis, PTX3 expression was significantly elevated in malignant tissues relative to healthy thyroid counterparts, in which it was entirely absent; however, its overall expression levels remained low to moderate across most malignant samples. CD68 and tryptase showed variable patterns, with a higher abundance of macrophages and mast cells in carcinomas and a significant association between mast cell presence and thyroid cancer (p = 0.0025). Conclusions: Our findings suggest that increased PTX3 levels may indicate an active inflammatory response or tissue stress linked to thyroid nodular disease. Nevertheless, its specificity for distinguishing benign from malignant lesions has yet to be determined. Its strong local expression in thyroiditis and consistently low expression in most carcinomas further support the concept that the long pentraxin PTX3 plays an important role in innate immune activation and inflammation-driven thyroid tissue remodeling. Additional studies are needed to better define its potential prognostic value in thyroid carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.